Sharon Moe, MD
Nephrology · Indianapolis, INNPI 1851356547
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,760 of the $7,064 with a category attached, or 95.7%. Ardelyx, Inc. accounts for 78.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $3,452 and has fallen 98.6% since, to $49 in 2024.
Across 13 payments — averaging $543.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$6K
- Novo Nordisk AS$1K
- Amgen$86
- Radius Health, Inc.$52
- Alnylam Pharmaceuticals Inc.$19
- Travere Therapeutics, Inc.$3
Across 8 payments — averaging $37,954 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$190K
- Vertex$102K
- Amgen$12K
What the payments were for
- Consulting fees$6,76096%
- Food & beverage$2634%
- Education$411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 6 | $5,544 |
| Novo Nordisk AS | 1 | $1,360 |
| Amgen | 3 | $86 |
| Radius Health, Inc. | 1 | $52 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$2,144
- Victoza$1,360
How this compares
$7,064 in reported general payments places this provider in the 85th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 15 | $21,750 |
| Potassium Chloride | 23 | $2,939 |
| Potassium Citrate ErPotassium Citrate | 11 | $2,344 |
| Chlorthalidone | 52 | $1,195 |
| Spironolactone | 15 | $607 |
| Losartan Potassium | 39 | $576 |
| Tamsulosin Hcl | 36 | $470 |
| Allopurinol | 27 | $410 |
| Metoprolol Succinate | 23 | $398 |
| Doxazosin Mesylate | 13 | $395 |
| Klor-Con M20Potassium Chloride | 13 | $388 |
| Indapamide | 13 | $360 |
| Amlodipine Besylate | 41 | $267 |
| Carvedilol | 26 | $198 |
| Hydrochlorothiazide | 22 | $116 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Indianapolis
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Simit DoshiIndianapolis$63K
- Arjun SinhaIndianapolis$50K
- Brent MillerIndianapolis$46K
- James ElliottIndianapolis$37K
- Nupur GuptaIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.